Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100 million for its AI-powered drug discovery operations. Incubated by Flagship Pioneering, Generate applies AI ...

The Northwest’s only commercial nuclear power plant, the Columbia Generating Station, was manually shut down early Thursday morning due to a mechanical problem. Energy Northwest workers shut the plant ...

Abstract: Handwriting verification has stood as a steadfast identity authentication method for decades. However, this technique risks potential privacy breaches due to the inclusion of personal ...

Abstract: Generative artificial intelligence has become the focus of the intelligent education field, especially in the generation of personalized learning resources. Current learning resource ...

Implement a text generation program using a Markov chain language model. The program will "learn" from a corpus of text (like Shakespeare or Darwin) and generate new text in a similar style using ...

Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year. 2025 was a slow year for IPOs, with ...

Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. The Flagship-founded biotech has yet to set out how many ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Generate:Biomedicines raised ...

Generate is indicative of a more mature startup that may have a better chance of succeeding in today’s markets. Industry IPOs peaked in 2021, resulting in a flood of companies whose early science didn ...

New York Post may be compensated and/or receive an affiliate commission if you click or buy through our links. Featured pricing is subject to change. We’re not going to string you along here.